Highlights
- Cardiovascular disease (CVD) mortality among individuals with diabetes has declined by up to 25.4% every five years in several high-income jurisdictions, signaling a major success in preventive cardiology and metabolic management.
- Dementia-related mortality is rising sharply among people with diabetes, independent of age, appearing as a significant new threat in aging populations.
- Cancer has surpassed CVD as the leading cause of death in people with diabetes in more than one-third of the jurisdictions studied.
- Despite improvements in absolute mortality, the mortality rate ratio (MRR) between people with and without diabetes remains largely stable, indicating that the relative disadvantage of having diabetes persists.
Background
For the better part of the last century, diabetes mellitus has been considered a cardiovascular equivalent. Clinicians have focused primarily on the prevention of myocardial infarction, stroke, and heart failure as the ultimate goals of diabetes care. This focus was justified: cardiovascular disease (CVD) was the primary driver of the reduced life expectancy associated with hyperglycemia. However, the last two decades have witnessed a revolution in cardiovascular therapeutics, including the widespread use of statins, renin-angiotensin-system inhibitors, and more recently, SGLT2 inhibitors and GLP-1 receptor agonists with proven cardioprotective benefits.
As life expectancy for people with diabetes increases due to better CVD management, the epidemiological profile of the disease is shifting. Patients are now living long enough to develop non-communicable diseases that were previously overshadowed by early cardiovascular death. This review synthesizes the findings of a major multinational study (PMID: 41819111) alongside recent evidence regarding metabolic health and nutritional adequacy to provide a comprehensive overview of the new mortality trends in diabetes.
Key Content
A Multinational Synthesis of Mortality Trends
The landmark study by Magliano et al. (2026) utilized representative administrative datasets from 11 high-income jurisdictions, covering 1.7 billion person-years and 13.7 million deaths between 2000 and 2023. This scale provides an unprecedented view of how the “diabetes death” has evolved in the 21st century. The study’s primary strength lies in its ability to compare cause-specific mortality between those with and without diabetes using age- and sex-standardized Poisson models.
The Decline of Cardiovascular and Diabetes-Specific Mortality
In every jurisdiction analyzed, CVD mortality rates fell. Among people with diabetes, the 5-year declines were substantial, ranging from 8.3% to 25.4%. This trend reflects the efficacy of modern multi-factorial management protocols—targeting blood pressure, lipids, and glucose simultaneously. Furthermore, mortality specifically attributed to diabetes itself (e.g., acute metabolic crises like ketoacidosis) also declined in most regions, suggesting improvements in acute care and patient education.
Interestingly, while absolute rates fell, the Mortality Rate Ratio (MRR) for CVD remained stable in most regions. This means that while people with diabetes are less likely to die of a heart attack than they were 20 years ago, they are still significantly more likely to do so than their peers without diabetes. A notable exception was Lithuania, where the CVD MRR fell by 7.6% every five years, indicating that the gap between the diabetic and non-diabetic populations is closing faster there than elsewhere.
The Emergence of Cancer as a Primary Cause of Death
As CVD mortality wanes, cancer mortality has remained relatively stable or declined much more slowly. By the end of the study period (2023), cancer had become the leading cause of death for people with diabetes in four out of 11 jurisdictions (36%). This shift is critical for clinical practice. Traditionally, diabetes care has not emphasized cancer screening as heavily as cardiovascular screening. However, the data suggest that the “oncological burden” of diabetes—potentially driven by hyperinsulinemia, chronic inflammation, and shared risk factors like obesity—now rivals the cardiovascular burden.
The Dementia Paradox
The most striking finding in recent longitudinal data is the marked increase in dementia-related mortality. In six of the seven jurisdictions with available data, dementia mortality increased significantly for people with diabetes. In Denmark and Scotland, the MRR for dementia actually increased (8.0% and 11.4% 5-year changes, respectively). This suggests that not only is dementia becoming more common as the population ages, but diabetes may be conferring an increasing relative risk for fatal neurodegeneration. This “Dementia Paradox” presents a significant challenge: we are successfully keeping patients alive long enough to develop cognitive diseases for which we currently have fewer therapeutic interventions than we do for CVD.
Nutritional and Metabolic Context
Translating these mortality trends into preventive action requires a focus on lifestyle and metabolic health. Recent research into the EAT-Lancet diet (PMID: 41692025) suggests that sustainable, plant-heavy dietary patterns can provide adequate micronutrient intake and may play a role in mitigating the chronic inflammation associated with both cancer and dementia. Furthermore, the development of oral small-molecule GLP-1 receptor agonists (PMID: 41421831) offers new avenues for treating the twin epidemics of obesity and type 2 diabetes, which are the root causes of the shifting mortality patterns observed in the Magliano study.
Expert Commentary
The transition from cardiovascular-dominant mortality to a more diversified profile including cancer and dementia requires a paradigm shift in diabetes clinics. We are moving from a “save the heart” model to a “preserve the person” model. The stability of the MRR across most causes of death is a sobering reminder that diabetes remains a potent accelerator of biological aging. Even as we improve absolute outcomes, the relative risk associated with the diabetic state remains remarkably persistent.
Mechanistically, the rise in dementia may be linked to “type 3 diabetes” concepts—insulin resistance within the central nervous system—or simply the result of surviving long enough to express late-life phenotypes. The shift toward cancer as a leading cause of death also necessitates a re-evaluation of screening guidelines. Should a diagnosis of Type 2 Diabetes trigger more aggressive screening for colorectal, pancreatic, or breast cancer? Current evidence suggests we should at least ensure that diabetes patients are as adherent to age-appropriate cancer screenings as the general population, as they are now more likely to die from malignancy than from a myocardial infarction in many settings.
One controversy remains: is the increase in dementia mortality a true increase in incidence, or a change in diagnostic coding and awareness? While some of the rise is certainly due to better recognition, the fact that the MRR increased in some jurisdictions suggests a genuine biological divergence in risk between those with and without diabetes.
Conclusion
The management of diabetes in high-income settings has achieved a historic victory in reducing cardiovascular mortality. However, this success has revealed new frontiers in the form of cancer and dementia. Clinical guidelines must now evolve to reflect these trends, emphasizing early cancer detection and cognitive health alongside traditional metabolic markers. Future research should prioritize the mechanisms linking diabetes to neurodegeneration and investigate whether newer agents like GLP-1 RAs and SGLT2is can stem the tide of non-cardiovascular deaths as effectively as they have reduced heart failure and stroke. The goal of modern diabetes care is no longer just extending life, but ensuring the quality of those additional years by preventing the devastating impacts of cancer and cognitive decline.
References
- Magliano DJ, et al. Trends in cause-specific mortality among people with and without diabetes in high-income settings: a multinational, population-based study. Lancet Diabetes Endocrinol. 2026. PMID: 41819111.
- Stubbendorff A, et al. Nutritional adequacy of the EAT-Lancet diet: a Swedish population-based cohort study. Lancet Planet Health. 2027. PMID: 41692025.
- Buse JB, et al. Oral small-molecule GLP-1 receptor agonist for type 2 diabetes and obesity. Lancet. 2026. PMID: 41421831.
- CASSANDRA Trial Investigators. Preoperative mFOLFIRINOX versus PAXG for pancreatic ductal adenocarcinoma. Lancet. 2026. PMID: 41275879.
